Author:incardatheraadmin

January 19, 2021 In News, Press Releases

InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation

Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular...

January 2, 2021 In News

Grace Colón Joins the First Rounders Podcast

Grace Colón joins the First Rounders Podcast (aired on 1/2/21). The conversation covers growing up in San Juan; her love musical theater; and how grad school at MIT guided her toward a career in entrepreneurship.  https://play.acast.com/s/naturebiotechnologypodcast/gracecolon...

November 13, 2020 In Events, News

InCarda Therapeutics to Present Preliminary Phase 2 Data at American Heart Association 2020 Scientific Sessions (Nov. 13-17, 2020)

On Friday, November 13 at 9:00am CT/10:00am ET, Dr. Harry Crijns, Clinical Electrophysiologist from Maastricht University Medical Center in the Netherlands, will present data from the open-label, dose-escalation Part A portion of InCarda’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in...

November 13, 2020 In Press Releases

InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020

Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF)  Provides Roadmap for Start of Pivotal Phase 3 in Medically Supervised Setting in 2021 San Francisco, CA...

October 21, 2020 In News

InCarda Therapeutics featured in Endpoints News

InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “This is especially exciting at a time when more...

October 21, 2020 In News

InCarda Therapeutics featured in FierceBiotech News

InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “What we're doing is a completely new way of...